Navneet Omprakash Soni*
Centre for Research in Molecular Pharmacology, Shramik coloney, Laxminagar, Sangli Maharashtra, India
*Address for Correspondence: Dr. Navneet Omprakash Soni, Research scholar, Department of Pharmacology, Centre for Research in Molecular Pharmacology, Maharashtra, India
ABSTRACT- Transient Receptor Potential Canonical (TRPC6) assumes vital part in pathophysiology of DN and is up-regulated by angiotensin II, high glucose level, Transforming growth factor beta (TGFβ), and intercede podocyte damage in Diabetes Mellitus focusing on TRPC6 may reduce podocyte damage and proteinuria. From different investigation and proof gave by analyst and author work on pathophysiological part of TRPC 6 and the medications which modify or restrain TRPC6 or its downstream molecular target propose that TRPC6 is novel molecular target. Recently distinguished ROS/TRPC6 pathway will cover the best approach to new, reassuring restorative systems to target kidney ailments, especially Diabetic Nephropathy.
Key-words- Diabetic nephropathy, TRPC6, Podocyte Injury, Proteinuria